[go: up one dir, main page]

MX2018005194A - Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. - Google Patents

Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.

Info

Publication number
MX2018005194A
MX2018005194A MX2018005194A MX2018005194A MX2018005194A MX 2018005194 A MX2018005194 A MX 2018005194A MX 2018005194 A MX2018005194 A MX 2018005194A MX 2018005194 A MX2018005194 A MX 2018005194A MX 2018005194 A MX2018005194 A MX 2018005194A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
same
fusion protein
prolonged action
fgf21 proteins
Prior art date
Application number
MX2018005194A
Other languages
English (en)
Other versions
MX391804B (es
Inventor
Hwan Kim Jun
LIM Seyoung
Seo Minji
Ho Choi Hyun
Kim Dohoon
Kyeong JU Mi
Young PARK Ju-
Hyun Choi Byung
Kyung Lee Jun
Gyun KIM Jong
Youn Nam Su
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2018005194A publication Critical patent/MX2018005194A/es
Publication of MX391804B publication Critical patent/MX391804B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención provee una proteí­na de fusión que comprende una proteí­na mutante de FGF21 y una región Fc de una inmunoglobulina. La proteí­na de fusión de conformidad con la presente invención presenta eficacia farmacológica, duración in vivo y estabilidad proteica mejoradas, y una composición farmacóutica que comprende la proteí­na de fusión como ingrediente activo se puede usar de manera efectiva como agente terapóutico para diabetes, obesidad, dislipidemia, sí­ndrome metabólico, enfermedad del hí­gado graso no alcohólico o esteatohepatitis no alcohólica.
MX2018005194A 2015-10-28 2016-10-28 Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. MX391804B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150150574A KR102668200B1 (ko) 2015-10-28 2015-10-28 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
PCT/KR2016/012288 WO2017074117A1 (en) 2015-10-28 2016-10-28 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same

Publications (2)

Publication Number Publication Date
MX2018005194A true MX2018005194A (es) 2018-07-06
MX391804B MX391804B (es) 2025-03-21

Family

ID=58630685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005194A MX391804B (es) 2015-10-28 2016-10-28 Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.

Country Status (23)

Country Link
US (3) US11142557B2 (es)
EP (2) EP3744731B1 (es)
JP (3) JP7303629B2 (es)
KR (1) KR102668200B1 (es)
CN (1) CN108290937B (es)
AU (3) AU2016346864B2 (es)
BR (1) BR112018008676A2 (es)
CA (1) CA3003109A1 (es)
CY (1) CY1123307T1 (es)
DK (1) DK3368554T3 (es)
ES (2) ES2815540T3 (es)
HR (1) HRP20201392T1 (es)
HU (2) HUE051036T2 (es)
LT (1) LT3368554T (es)
MX (1) MX391804B (es)
PL (1) PL3744731T3 (es)
PT (1) PT3368554T (es)
RS (1) RS60725B1 (es)
RU (1) RU2741087C2 (es)
SI (1) SI3368554T1 (es)
SM (1) SMT202000468T1 (es)
WO (1) WO2017074117A1 (es)
ZA (1) ZA201802002B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
AU2017358289C1 (en) * 2016-11-10 2025-05-08 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
EP4470551A3 (en) 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
US11560416B2 (en) * 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives
EP3678686A1 (en) * 2017-09-08 2020-07-15 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
SMT202400277T1 (it) 2017-12-22 2024-09-16 Novartis Ag Trattamento di disturbi metabolici con varianti di fgf21
US20210275643A1 (en) 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
JP7664168B2 (ja) * 2019-03-05 2025-04-17 サンシャイン・レイク・ファーマ・カンパニー・リミテッド ポリペプチド分子及びその適用
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
WO2021152396A1 (en) * 2020-01-31 2021-08-05 89Bio Ltd. Methods for promoting weight loss
WO2022194260A1 (en) * 2021-03-19 2022-09-22 Sunshine Lake Pharma Co., Ltd. Uses of fgf21 polypeptides and fusion polypeptides thereof
CN113198002A (zh) * 2021-05-12 2021-08-03 上海交通大学医学院附属第九人民医院 一种用于治疗非酒精性脂肪肝的肝细胞因子bmp9
TW202317645A (zh) * 2021-07-05 2023-05-01 大陸商上海翰森生物醫藥科技有限公司 一種融合蛋白及其醫藥用途
CN113717269B (zh) * 2021-08-31 2022-04-19 赣江中药创新中心 一种重组的变体fgf21蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
PL2126106T3 (pl) 2007-02-23 2018-03-30 Sk Chemicals Co., Ltd. Sposób produkcji i oczyszczania czynnika VIII i jego pochodnych
ES2415604T3 (es) * 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
WO2009020802A2 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
KR101651703B1 (ko) * 2008-10-10 2016-08-26 암젠 인크 Ｆｇｆ21 돌연변이체 및 이의 용도
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
WO2010129600A2 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
JP2012529463A (ja) 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
ES2543634T3 (es) 2010-01-22 2015-08-20 Novo Nordisk A/S Proceso para preparación de FGF-21 con grado de O-glicosilación bajo
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
EP2595647A1 (en) * 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2661445A2 (en) * 2011-01-04 2013-11-13 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
JP2014526441A (ja) 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド １型糖尿病の治療における使用のためのｆｇｆ２１
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
CN102558358A (zh) 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
US9475856B2 (en) * 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
KR102854572B1 (ko) 2014-10-24 2025-09-02 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
CN107750159B (zh) * 2015-06-23 2021-10-29 英特维特国际股份有限公司 用于消毒的饮用水的含有维生素的异噁唑啉溶液
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
AU2017358289C1 (en) * 2016-11-10 2025-05-08 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
EP4470551A3 (en) 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
US11560416B2 (en) 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives

Also Published As

Publication number Publication date
CY1123307T1 (el) 2021-12-31
EP3744731B1 (en) 2025-06-18
WO2017074117A1 (en) 2017-05-04
CN108290937A (zh) 2018-07-17
RU2018119141A (ru) 2019-12-02
EP3368554A1 (en) 2018-09-05
HK1257375A1 (zh) 2019-10-18
JP2024075620A (ja) 2024-06-04
RU2741087C2 (ru) 2021-01-22
CN108290937B (zh) 2022-03-08
AU2016346864B2 (en) 2021-03-18
SMT202000468T1 (it) 2020-11-10
PT3368554T (pt) 2020-09-10
EP3368554A4 (en) 2019-06-19
JP2018534929A (ja) 2018-11-29
RS60725B1 (sr) 2020-09-30
SI3368554T1 (sl) 2020-10-30
US20220002367A1 (en) 2022-01-06
PL3744731T3 (pl) 2025-09-08
JP2021184727A (ja) 2021-12-09
HRP20201392T1 (hr) 2020-11-27
CA3003109A1 (en) 2017-05-04
JP7303629B2 (ja) 2023-07-05
BR112018008676A2 (pt) 2018-11-27
AU2024259757A1 (en) 2024-11-28
US11142557B2 (en) 2021-10-12
EP3744731C0 (en) 2025-06-18
ES2815540T3 (es) 2021-03-30
HUE071984T2 (hu) 2025-10-28
KR102668200B1 (ko) 2024-05-23
RU2018119141A3 (es) 2020-03-24
EP3744731A1 (en) 2020-12-02
AU2016346864A1 (en) 2018-05-10
NZ741431A (en) 2025-05-02
US20240279296A1 (en) 2024-08-22
EP3368554B1 (en) 2020-08-05
US20180305428A1 (en) 2018-10-25
MX391804B (es) 2025-03-21
ES3035658T3 (en) 2025-09-08
LT3368554T (lt) 2020-09-25
AU2021204115A1 (en) 2021-07-15
DK3368554T3 (da) 2020-08-31
KR20170049319A (ko) 2017-05-10
HUE051036T2 (hu) 2021-01-28
JP7453943B2 (ja) 2024-03-21
ZA201802002B (en) 2019-05-29

Similar Documents

Publication Publication Date Title
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
BR112018008805A8 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
BR112016026811A2 (pt) formulação de anticorpo
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
BR112015023391A8 (pt) formulações de conjugados anticorpo-droga anti-egfr
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
PE20160527A1 (es) Formulaciones de adenovirus mejoradas
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2015002835A1 (es) Nuevos derivados de piridina
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2024012898A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX390441B (es) Formulaciones liquidas de fosfaplatino.
MD4763B1 (ro) Compoziţie farmaceutică